Preferred Label : tissue plasminogen activator;

MeSH definition : A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.;

MeSH synonym : alteplase; plasminogen activator, tissue type; tissue-type plasminogen activator; t plasminogen activator; tissue activator d 44; plasminogen activator, tissue; tissue activator d-44; Tisokinase; tissue type plasminogen activator; ttpa; t-plasminogen activator; plasminogen activator, tissue-type;

CISMeF synonym : activator, t-plasminogen; activator, tissue plasminogen; activator, tissue-type plasminogen; Hoffmann-La roche brand of alteplase; alteplase genentech brand; alteplase promeco brand; boehringer ingelheim brand of alteplase; genentech brand of alteplase; hoffmann la roche brand of alteplase; promeco brand of alteplase;

MeSH hyponym : actilyse; activase; Lysatec rt-PA; Lysatec rt PA; Lysatec rtPA;

MeSH Related Number : 105857-23-6 (Alteplase);

Registry Number MeSH : EC 3.4.21.68;

Wikipedia link : https://en.wikipedia.org/wiki/Tissue plasminogen activator;

Is substance : O;

UNII : EC 3.4.21.68;

Details


Main resources

You can consult :

A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.

https://ansm.sante.fr/informations-de-securite/actilyse-alteplase-extension-dutilisation-chez-ladolescent-16-ans-ou-plus-dans-laccident-vasculaire-cerebral-ischemique-a-la-phase-aigue
2018
false
false
false
France
French
guidelines for drug use
adolescent
Ischemic Stroke
acute disease
stroke
brain ischemia
tissue plasminogen activator
fibrinolytic agents
Alteplase 10mg powder and solvent for injection solution vial (product)
Alteplase 20mg powder and solvent for injection solution vial (product)
Alteplase 50mg powder and solvent for injection solution vial (product)
alteplase

---
http://www.has-sante.fr/portail/jcms/c_2621686/fr/actilyse
2016
true
France
French
Ischemic stroke
alteplase
brain ischemia
fibrinolytic agents
fibrinolytic agents
infusions, intravenous
tissue plasminogen activator
tissue plasminogen activator
treatment outcome
stroke
evaluation of the transparency committee

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67177673
2013
France
summary of product characteristics
powders
injections
tissue plasminogen activator

---
https://www.minerva-ebp.be/fr/article/82
2013
false
false
minerva-ebm.be
Belgium
French
critical appraisal or critical reading
stroke
endovascular procedures
fibrinolytic agents
tissue plasminogen activator
treatment outcome
comparative study

---
https://www.ema.europa.eu/medicines/human/EPAR/Rapilysin
2012
United Kingdom
French
English
syndication feed
tissue plasminogen activator
recombinant proteins
fibrinolytic agents
myocardial infarction
treatment outcome
drug evaluation
reteplase
reteplase
tissue plasminogen activator
recombinant proteins
drug evaluation
summary of product characteristics
package leaflet

---
http://www.has-sante.fr/portail/jcms/c_1297825/actilyse-alteplase-antithrombotique
http://www.has-sante.fr/portail/jcms/c_1297822/actylise-synthese-04072012
2012
France
French
Ischemic stroke
alteplase
brain ischemia
fibrinolytic agents
fibrinolytic agents
infusions, intravenous
tissue plasminogen activator
tissue plasminogen activator
treatment outcome
stroke
guidelines for drug use
evaluation of the transparency committee

---
https://www.ema.europa.eu/medicines/human/EPAR/Metalyse
2011
false
United Kingdom
French
English
syndication feed
Contraindications, Procedure
myocardial infarction
thrombolytic therapy
tissue plasminogen activator
tissue plasminogen activator
tissue plasminogen activator
tissue plasminogen activator
fibrinolytic agents
fibrinolytic agents
fibrinolytic agents
fibrinolytic agents
treatment outcome
drug evaluation
injections, intravenous
tenecteplase
tissue plasminogen activator
drug evaluation
summary of product characteristics
package leaflet
tissue plasminogen activator
Contraindications, Drug
Tenecteplase
Tenecteplase

---
http://www.john-libbey-eurotext.fr/fr/revues/medecine/nro/e-docs/00/04/54/55/article.phtml
2010
France
French
tissue plasminogen activator
injections, intravenous
injections, Intra-Arterial
fibrinolytic agents
stroke
thrombectomy
recovery of function
cerebral arteries
treatment outcome
thrombolytic therapy
intracranial thrombosis
alteplase
comparative study
journal article

---
http://www.john-libbey-eurotext.fr/fr/revues/medecine/nro/e-docs/00/04/47/12/resume.phtml
2009
France
French
treatment outcome
thrombolytic therapy
cerebral infarction
alteplase
hemorrhage
tissue plasminogen activator
aged, 80 and over
journal article

---
http://www.has-sante.fr/portail/jcms/c_893727/actilyse-2-mg-alteplase-anticoagulant-injectable
2009
France
evaluation of the transparency committee
injections
anticoagulants
tissue plasminogen activator

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-10/actilyse_-_ct-6722_2009-10-22_14-53-8_981.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/actilyse_ct_6722.pdf
http://www.has-sante.fr/portail/jcms/c_866792/actilyse
2009
France
French
English
alteplase
fibrinolytic agents
treatment outcome
fibrinolytic agents
tissue plasminogen activator
adult
child
catheterization, central venous
thrombosis
renal dialysis
catheters, indwelling
tissue plasminogen activator
evaluation of the transparency committee
central venous catheters

---
https://www.cadth.ca/sites/default/files/pdf/194_No38_alteplase_preassess_e.pdf
https://www.cadth.ca/sites/default/files/pdf/194_No38_alteplase_preassess_f1.pdf
2004
Canada
French
English
fibrinolytic agents
tissue plasminogen activator
stroke
canada
Evidence-Based medicine
treatment outcome
tissue plasminogen activator
fibrinolytic agents
Cost-Benefit analysis
risk assessment
acute disease
brain ischemia
tissue plasminogen activator
fibrinolytic agents
alteplase
drug evaluation
bibliography

---
https://www.cadth.ca/sites/default/files/pdf/138_tenecteplase_cetap_f.pdf
https://www.cadth.ca/sites/default/files/pdf/138_tenecteplase_cetap_e.pdf
2001
Canada
French
English
fibrinolytic agents
myocardial infarction
treatment outcome
tissue plasminogen activator
canada
Evidence-Based medicine
injections, intravenous
acute disease
clinical trials as topic
tissue plasminogen activator
fibrinolytic agents
drug costs
fibrinolytic agents
tissue plasminogen activator
tenecteplase
tissue plasminogen activator
drug evaluation
bibliography
Tenecteplase
Tenecteplase
Tenecteplase

---
Nous contacter.
14/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.